CSL Expected to See Potential Medium-Term Earnings Upside, Says Jefferies
MT Newswires Live
Nov 07
CSL (ASX:CSL) is expected to see potential upside to its earnings over the medium term, helped by the potential for yield improvements, according to a Thursday Jefferies note.
The investment firm said the company's commentary was cautious overall at its Behring Capital Markets Day in Chicago, but Jefferies believes that the company's Horizons 1 and 2 programs are expected to deliver about a 22% improvement in immunoglobulin yield across CSL Behring by fiscal year 2030.
Jefferies kept a buy rating on CSL with a price target of AU$240.
The company's shares rose almost 1% in recent Friday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.